Health Law Daily Wrap Up, ANTITRUST—E.D. Pa.: Generic drug pricing MDL claims advance as court sustains overarching conspiracy allegations, (May 7, 2026)

By Martin A. Steinberg, J.D.

Dozens of generic-drug manufacturers allegedly engaged in a multiyear antitrust conspiracy involving “fair share” market-allocation agreements, bid rigging, and price fixing for numerous generic pharmaceutical products.

The federal district court in Philadelphia, Pennsylvania largely denied motions to dismiss an opt-out action brought by self-funded direct action plaintiffs in the long-running generic pharmaceutical pricing antitrust multidistrict litigation. Plaintiffs alleged that dozens of pharmaceutical companies participated in an overarching conspiracy, beginning in 2009, to allocate customers and markets, rig bids, and fix prices for numerous generic drugs through “fair share” agreements. The court held that the amended complaint plausibly alleged the same overarching conspiracy that was previously found sufficient in related MDL complaints, including parallel price increases, market conditions that gave Defendants a motive to conspire, conduct contrary to their self-interest, and communications implying a traditional conspiracy. The court also sustained claims against Novartis AG and Sandoz AG, finding sufficient allegations and supporting evidence that they were deeply involved in Sandoz’s U.S. generic-drug business and alleged anticompetitive conduct, and that the 2023 Sandoz spin-off supported voidable-transfer claims. However, the court dismissed claims against Emcure Pharmaceuticals and Strides Pharma because they were not named in the earlier end-payer class action and therefore did not benefit from American Pipe or supplemental-jurisdiction tolling. It also dismissed claims against West-Ward Pharmaceuticals and Roxane without prejudice because the complaint confusingly grouped several Hikma, West-Ward, and Roxane entities together (In re: Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:24-cv-01430-CMR (E.D. Pa. May 4, 2026)).

Background. American Airlines, Inc.; Aramark Services, Inc.; General Motors LLC; Lowe’s Companies, Inc.; Lumen Technologies, Inc.; Lumen Technologies Service Group, LLC; RTX Corporation; Target Corporation; US Foods, Inc. alleged that, beginning in 2009, the fifty-five named Defendants entered into illegal “fair share” agreements to allocate customers and markets, rig bids, and fix prices in violation of federal and state antitrust laws. The action was filed eight years after similar cases had been consolidated in the Eastern District of Pennsylvania MDL, and Plaintiffs chose to bypass, or opt out of, the end-payer class action. After Plaintiffs amended their complaint, multiple Defendants filed seven motions to dismiss, raising various challenges.

The court also addressed the extensive sealing of the amended complaint and motion-to-dismiss briefing. Because many filings and allegations remained under seal due to confidentiality designations in earlier MDL pretrial orders, the public versions contained numerous redactions of information the court deemed important. Emphasizing that the litigation involves a matter of great public interest, the court stated that it was time to reassess whether continued sealing remained appropriate. The court therefore ordered the parties who moved to seal the amended complaint and the motions to dismiss to show good cause for keeping those materials from public view.

Overarching antitrust conspiracy. Several Defendants argued that Plaintiffs had not plausibly alleged a broad conspiracy across the generic-drug market. The court rejected that argument, finding that the amended complaint’s overarching-conspiracy allegations matched those previously held sufficient in other MDL complaints. Plaintiffs alleged parallel price increases; market conditions that gave Defendants a motive to conspire; pricing and bidding conduct contrary to competitive self-interest; and facts implying a traditional conspiracy, including inter-defendant communications, trade-association involvement, and ongoing government investigations.

The court also credited allegations of an industry “fair share” code under which competitors were entitled to their share of markets for particular generic drugs or groups of drugs. It emphasized that the conspiracy could not be viewed in isolated pieces because Defendants allegedly risked retribution across their drug portfolios if they failed to honor the arrangement. The court therefore denied the motions to dismiss the overarching-conspiracy allegations.

Statute of limitations. Several Defendants argued that the complaint was untimely. The court declined to decide when the limitations periods began to run, explaining that similar limitations challenges in the MDL had been deferred until after discovery. But the court found it appropriate to decide whether the earlier end-payer class action could toll plaintiffs’ claims.

The court held that American Pipe v. Utah tolling applied to the federal claims and that 28 U.S.C. § 1367(d) tolled related state-law claims that were part of the same civil action by supplemental jurisdiction. The court reasoned that putative class members need not wait for class certification or its denial before filing individual lawsuits and invoking class-action tolling. Because the direct action Plaintiffs were members of the end-payer class when they filed this 2024 action, their overlapping claims could benefit from tolling, while claim-specific accrual issues remained to be discovered.

The court drew an important limitation, however: tolling applies only to Defendants named in the earlier end-payer class action. The amended complaint included claims against Emcure Pharmaceuticals Ltd. and Strides Pharma, but Plaintiffs admitted those two Defendants had not been sued in the end-payer action. The court found no authority allowing American Pipe or § 1367(d) tolling against Defendants who were not part of the earlier class case, even if they had been named in other MDL complaints. It therefore dismissed the claims against Emcure and Strides, while leaving the remaining parties to use discovery to determine when the limitations periods began to run for specific claims, dosages, and formulations.

Novartis AG and Sandoz AG. Next, the court denied Novartis AG’s and Sandoz AG’s motions to dismiss, holding that the amended complaint and Plaintiffs’ exhibits plausibly alleged their deep involvement in Sandoz’s U.S. generic-drug business, the alleged antitrust conspiracy, and the 2023 Sandoz spin-off.

The complaint alleged that Novartis relaunched the Sandoz brand in 2003 through wholly owned entities that functioned as a single enterprise, with Novartis exercising oversight and strategic direction over Sandoz’s manufacturing, marketing, pricing, and sales. Plaintiffs also alleged overlapping officers and directors, shared systems and branding, centralized services, and Novartis' control over Sandoz communications and business information.

The court highlighted allegations that Novartis approved Sandoz's pricing decisions, dictated “fair share” arrangements, received competitor pricing intelligence, coordinated Sandoz’s response to a DOJ price-fixing investigation, authorized Sandoz’s deferred prosecution agreement and $195 million fine, and benefited from MDL settlements that released Novartis and Sandoz AG. Plaintiffs also alleged that Novartis directed coordination with Mylan over generic Diovan, a financially important drug after patent expiration, by pressuring a Sandoz executive to obtain competitive intelligence on Mylan’s launch.

The court also credited allegations that Novartis structured the 2023 spin-off to protect proceeds from the alleged conspiracy while shifting liabilities to Sandoz. The transaction allegedly required Sandoz and Sandoz AG to pay Novartis $3.3 billion, assume price-fixing and opioid liabilities, indemnify Novartis and related persons, and make additional payments for unspecified technology transfers.

The court rejected Novartis’s subject-matter jurisdiction challenge, finding injury from overcharges, causation through Novartis’s alleged direction of Sandoz, and redressability through injunctive relief aimed at stopping transfers of alleged ill-gotten gains. It also found a prima facie showing of personal jurisdiction, alter ego jurisdiction, and agency jurisdiction based on Plaintiffs’ allegations and exhibits demonstrating Novartis's involvement in pricing approvals, supply-chain functions, board actions, shared systems, electronic information controls, overlapping management, integrated operations, unified branding, and parent-level control. Because the federal claims survived and the state claims arose from the same conduct, the court retained supplemental jurisdiction.

Finally, the court rejected the Rule 9(b) challenge to the New Jersey Uniform Voidable Transfer Act claims, finding that Plaintiffs pleaded the “who, what, when, where, and how” of the alleged spin-off scheme and multiple badges of fraud. The court also held that the antitrust allegations sufficiently pleaded the participation of Novartis and Sandoz AG in the overarching conspiracy.

Mayne Pharma. Mayne Pharma’s motion to dismiss argued that the amended complaint failed to allege an agreement between Mayne and Heritage Pharmaceuticals, Inc., to rig prices or allocate market share. The court rejected that argument, finding that the complaint pleaded detailed communications and coordinated conduct involving Doxycycline Hyclate Delayed Release, or Doxy DR, an acne treatment, and oxycodone/acetaminophen, a painkiller.

As to Doxy DR, the complaint alleged that shortly before Mayne entered the market in February 2014, a Mayne accounts director spoke with a Heritage counterpart, leading the companies to target Mylan, which held 60 percent of the market. The complaint further alleged ongoing communications among Mayne and Heritage personnel about giving Mayne a greater market share without disrupting other alleged co-conspirators, culminating in an agreement for Mayne to overbid Heritage’s price to a customer in December 2014, and a continuing conspiracy through December 2015 to divide the Doxy DR market. The court also noted that a Heritage vice president later pleaded guilty to bid rigging, customer allocation, and price fixing involving drugs listed in the complaint.

As to oxycodone/acetaminophen, the complaint alleged that vendors and manufacturers raised the price of a 100-count bottle of 10/325 mg pills from roughly $18 in 2011 and 2012 to $80 by December 2013, despite no supply shortage, demand spike, or other market explanation. Mayne’s president allegedly encouraged his sales team to coordinate with competitors about which customers Mayne should target when it entered the market in 2014, and Mayne allegedly charged the same price its competitors had conspired to charge.

The court found Mayne’s motion misleading because the complaint alleged direct communications followed by coordinated pricing and market-allocation conduct. Those allegations were sufficient at the pleading stage, though Mayne could challenge them later at summary judgment or trial. Mayne’s motion to dismiss was denied.

West-Ward Pharmaceuticals and Roxane. Next, the court addressed West-Ward Pharmaceuticals’ and Roxane Pharmaceuticals’ motion to dismiss, which the court granted without prejudice. The court found that the amended complaint did not clearly connect the alleged misconduct to the particular West-Ward, Roxane, or Hikma entities involved.

The complaint used “West-Ward” to refer collectively to several companies, including Hikma USA, Hikma Pharmaceuticals, West-Ward Columbus, West-Ward Pharmaceuticals, and Hikma Labs. The court found that this grouping created confusion, especially because the complaint later used different labels, including “Hikma/West-Ward,” “Hikma/Roxane,” and “Hikma.”

The court also rejected Plaintiffs’ attempt to rely on pleadings filed in other MDL cases rather than setting out the relevant allegations in their own complaint. Because the complaint had to stand on its own allegations, the court dismissed the claims against West-Ward Pharmaceuticals and Roxane, including alleged subsidiaries, predecessors, and successors, with leave to amend.

Ascend. The court denied Ascend Laboratories, LLC’s motion to dismiss claims involving Nimodipine and Silver Sulfadiazine, holding that the complaint adequately alleged communications and coordinated conduct involving both drugs. As to Nimodipine, the complaint alleged that after Ascend received approval to manufacture the drug in April 2014, Heritage vice president Jason Malek contacted an Ascend vice president and offered Ascend a one-third market share. Heritage and Ascend allegedly agreed that Heritage would raise prices, Ascend would charge a high price to avoid taking Heritage customers, and Heritage would stop selling to some customers so Ascend could gain market share at favorable pricing.

As to Silver Sulfadiazine, the complaint alleged that Ascend coordinated with Actavis in 2012 to raise prices to supracompetitive levels despite the absence of a supply shortage, a demand spike, or any other market explanation. The alleged coordination followed communications at industry meetings. The court held that competitor communications followed by parallel price increases were sufficient to support claims of concerted anticompetitive conduct at the pleading stage.

Several Defendants. Lastly, the court addressed several Defendants’ motions to dismiss, asserting that the complaint fails to identify specific drugs, dosages, formulations, or company-specific conduct with sufficient precision. Some Defendants argued that the complaint was not a “short and plain statement” because it failed to specify dosages and formulations for many drugs allegedly affected by the overarching conspiracy. Others argued that the complaint failed to allege sufficient facts to tie specific companies to anticompetitive conduct involving specific drugs. Amneal separately sought dismissal of claims involving Bethanechol Chloride, arguing that the complaint did not describe what Amneal did, when it acted, or with whom it allegedly conspired regarding that drug.

The court denied the motions. It emphasized that prior MDL opinions had already found an overarching conspiracy to fix prices and allocate market share for many generic drugs. The amended complaint contained specific allegations of communications, meetings, trade-group participation, and parallel drug pricing sufficient to support claims involving specific drugs. The court held that, as to the moving Defendants, the complaint adequately alleged the necessary “plus factors”: motive to join a price-fixing conspiracy, conduct contrary to self-interest, and facts implying a traditional conspiracy. Because the alleged conspiracy had to be viewed as a whole rather than dismembered into isolated parts, dismissal was not warranted.

The Case is No. 2:24-cv-01430-CMR.

Judge: Rufe, C.

Attorneys: Bryan Gray (Bartlit Beck LLP) for American Airlines, Inc.

Companies: American Airlines, Inc.; Actavis Holdco U.S., Inc.

Cases: CaseDecisions AntitrustNews GenericDrugNews PrescriptionDrugNews PennsylvaniaNews